Currently Viewing:
Currently Reading
Survey Identifies Americans' Preferences for Pain Management
November 20, 2017 – Jaime Rosenberg
How the Gut Microbiome Is Affecting Immunotherapy Response
November 20, 2017 – Laura Joszt
What We're Reading: Mandate Repeal Uncertainty; Destroying Antitrust Evidence; PTSD After Cancer
November 20, 2017 – AJMC Staff
This Week in Managed Care: November 17, 2017
November 17, 2017
Study Supports Use of Intravenous Golimumab in Treating Psoriatic Arthritis
November 17, 2017 – Kelly Davio
ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy
November 17, 2017 – AJMC Staff
AJMC® in the Press, November 17, 2017
November 17, 2017 – AJMC Staff
What We're Reading: Gene Therapy Guidelines; Opioid Overdose Costs; Unaware of Open Enrollment
November 17, 2017 – AJMC Staff
5 Things About the New Hypertension Guidelines
November 17, 2017 – Mary Caffrey

UCSF Researchers Identify Determinants of Coverage for Hereditary Cancer Panels

Surabhi Dangi-Garimella, PhD
A new study published in the Journal of the National Comprehensive Cancer Network dives deeper into understanding the major roadblocks to coverage of hereditary cancer panels.
In his 2015 State of the Union speech, former President Barack Obama called for additional investment in personalized medicine, which included the announcement of the Precision Medicine Initiative (PMI). However, discrepancies within payer policies on coverage of genetic tests was identified as a big barrier to the success of this program. A new paper published in the Journal of the National Comprehensive Cancer Network dives deeper into understanding the major roadblocks to coverage of hereditary cancer panels (HCPs).

HCPs, which test for multiple genes and can provide information on a person’s risk for several syndromes, can have a big impact on cancer risk assessment. However, these tests lack formal coverage. Led by Julia R. Trosman, PhD, adjunct assistant professor, TRANSPERS, Department of Clinical Pharmacy, University of California, San Francisco (UCSF), the researchers interviewed 11 major US payers covering more than 160 million lives.

“We believe that understanding payers’ coverage decision-making is imperative to ensuring future patient access to potentially transformative modalities and informing genetic research,” Trosman said. The study focused on private payers because they cover two-thirds of the US population.

The study identified the following barriers to coverage of these multigene panels:
  • Poor fit with coverage frameworks (100%)
  • Insufficient evidence (100%)
  • Departure from pedigree/family history–based testing toward genetic screening (91%)
  • Lacking rigor in the HCP hybrid research/clinical setting (82%)
  • Patient transparency and involvement concerns (82%)
Payers have developed different approaches to address these barriers, and they shared their ideas during the interview. They told the researchers, for example, that they would readily accept observational and pooled studies and registry data to confirm statistical significance, instead of confirmatory randomized clinical trials, which are much more rigorous to plan and conduct. Other recommendations included:
  • Developing evidence of actionability (82%)
  • Developing evidence of pathogenicity/penetrance (64%)
  • Creating infrastructure and standards for informing and recontacting patients (45%)
  • Separating research from clinical use in the hybrid clinical-research setting (44%)
  • Adjusting coverage frameworks (18%)
 “Many previous studies on reimbursement for genomic technologies, including our own, were focused on barriers to coverage,” said Trosman. “We are encouraged that the present study also identified opportunities that could be pursued to mitigate barriers.”

The authors conclude that their study informs 3 areas that can propel the precision medicine movement forward: incorporating payers’ evidentiary requirements into PMI’s research agenda; and leveraging payers’ recommendations and experience to keep patients informed and involved.


Trosman JR, Weldon CB, Douglas MP, et al. Payer coverage for hereditary cancer panels: barriers, opportunities, and implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017;15(2):219-228.

Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!